Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.
ACQ Bure AB, a Swedish acquisition company (Special Purpose Acquisition Company) listed on Nasdaq Stockholm and Yubico AB have signed a merger agreement and adopted a joint merger plan to combine ACQ and Yubico.
Vinge has advised CTEK AB (publ) on a fully guaranteed rights issue, which will provide CTEK with issue proceeds of approximately SEK 350 million before deduction of transaction costs.
Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.
Vinge has advised Smart Eye Aktiebolag (First North Growth Market) in connection with its fully secured rights issue which provided Smart Eye with MSEK 324 before transaction costs. The issue was fully subscribed and no guarantee commitments had to be utilised.
Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.
Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.
Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.
Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.
